N-hydroxyl thienopyrimidinedione derivative as well as preparation method and application thereof
By developing N-hydroxythienopyrimidindione derivatives as orthopoxvirus inhibitors, the side effects and insufficient treatment of existing anti-orthopoxvirus drugs have been solved, and significant antiviral against monkeypoxvirus and camelpoxvirus has been achieved. Active and low cytotoxic effects.
Patent Information
- Application Number
- CN202411354963.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-27
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-27
AI Technical Summary
The existing anti-orthopoxvirus drugs have side effects such as nephrotoxicity and gastrointestinal damage, and lack effective therapeutic drugs for emerging monkeypoxviruses, and are urgently needed for new anti-orthopoxvirus drugs.
An N-hydroxythienopyrimidindione derivative and its preparation method were developed, and it was proved through experiments that it has significant antiviral activity and low cytotoxicity as an orthopoxvirus inhibitor, and is used to prepare anti-orthopoxvirus drugs.
The novel N-hydroxythienopyrimidindione derivatives show significant antiviral activity against monkeypoxvirus and camelpoxvirus, which is better than the existing drug cidofovir, and has low cytotoxicity and has further research and development value.
Smart Images

Figure CN119080799A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic compound synthesis and pharmaceutical application, and specifically relates to an N-hydroxythienopyrimidinedione derivative and a preparation method thereof and application thereof as an anti-orthopoxvirus drug. Background Art
[0002] Poxvirus, belonging to the Poxviridae family, is a virus that can cause widespread pox diseases in humans and other animals. Currently, four genera of viruses are known to infect humans, including orthopoxvirus, parapoxvirus, yatapoxvirus and molluscumvirus. Among them, smallpox virus, monkeypox virus, cowpox virus and vaccinia virus, which belong to the orthopoxvirus genus, are relatively famous in the history of human epidemiology. With the eradication of smallpox virus in 1980 and the cessation of smallpox vaccination, monkeypox virus has become the most important orthopoxvirus infecting humans. On August 14, 2024, monkeypox epidemics broke out in many regions around the world. The World Health Organization declared the monkeypox epidemic a global public health emergency, which also sounded the alarm for the prevention and control of orthopoxviruses around the world.
[0003] Currently, there are three antiviral drugs approved for emergency treatment of smallpox outbreaks, namely cidofovir, brincidofovir and tecovir. Among them, cidofovir and brincidofovir are limited in their clinical use due to problems such as nephrotoxicity and damage to the gastrointestinal tract. In addition, there is no specific drug available for the emerging outbreak of monkeypox, and only tecovir was urgently approved by the European Medicines Agency for the treatment of monkeypox in 2022. Therefore, in response to the monkeypox virus epidemic crisis and the clinical needs of the gap in anti-orthopoxvirus drugs, it is urgent to discover new anti-orthopoxvirus drugs.
[0004] Summary of the invention
[0005] In view of the deficiencies in the prior art, the present invention provides an N-hydroxythienopyrimidinedione derivative and a preparation method thereof; the present invention also provides the use of the N-hydroxythienopyrimidinedione derivative as an orthopoxvirus inhibitor.
[0006] The technical solution of the present invention is as follows:
[0007] 1. N-Hydroxythienopyrimidinedione derivatives
[0008] An N-hydroxythienopyrimidinedione derivative, or a pharmaceutically acceptable salt, ester or prodrug thereof, having a structure shown in general formula I or II:
[0009]
[0010] n = 0, 1, 2 or 3;
[0011] R1 is: hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
[0012] R2 is: C1-C6 alkyl, OC1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered heterocycle, substituted or unsubstituted five-membered heterocycle, substituted or unsubstituted six-membered and five-membered heterocycle, substituted or unsubstituted six-membered and six-membered heterocycle, substituted or unsubstituted five-membered and five-membered heterocycle, substituted or unsubstituted benzo five-membered heterocycle, substituted or unsubstituted benzo six-membered heterocycle;
[0013] The substituents in R1 and R2 are selected from alkyl, cycloalkyl, methoxy, nitro, cyano, amino, trifluoromethyl, ester, halogen, 2,6-diF, 2,5-diF, 3,4-diF, 2,4-diF, 2-F,4-CF3, 3-F,4-CF3, CONH2, SO2NH2, SO2CH3, NHMe, NHCOMe, NHSO2Me or NHSO2CF3.
[0014] According to the preferred embodiment of the present invention,
[0015] R1 is methyl, ethyl, isopropyl, methylenecyclopropyl or methylenecyclobutyl;
[0016] n=1,
[0017] R2 is a substituted benzene ring having the general formula a;
[0018]
[0019] wherein R3 is F, Cl, Br, Me, OMe, CN, NO2, NH2, 2,6-diF, 2,5-diF, 3,4-diF, 2,4-diF, 2-F,4-CF3, 3-F,4-CF3, CONH2, SO2NH2, SO2CH3, NHMe, NHCOMe, NHSO2Me or NHSO2CF3.
[0020] Preferably according to the present invention, the pharmaceutically acceptable salt of the compound is sodium salt, hydrochloride, sulfate, tartrate or citrate.
[0021] According to the present invention, the N-hydroxythienopyrimidinedione derivative represented by general formula I or II is one of the following compounds:
[0022]
[0023] 2. Preparation method of N-hydroxythienopyrimidinedione derivatives
[0024] The preparation method of N-hydroxythienopyrimidinedione derivatives comprises the following steps: using 2-aminothiophene-3-carboxylic acid methyl ester as a starting material, reacting with carbonyldiimidazole and o-benzylhydroxylamine to form an intermediate compound 1 through cyclization; the intermediate compound 1 reacts with N-iodosuccinimide to form an intermediate compound 2 through iodination reaction (or 3-amino-5-iodothiophene-2-carboxylic acid methyl ester directly reacts with carbonyldiimidazole and o-benzylhydroxylamine to form an intermediate compound 2 through cyclization); the intermediate compound 2 reacts with potassium carbonate to form an intermediate compound 3 through nucleophilic substitution reaction; The intermediate compound 3 undergoes a Sonogaoka coupling reaction in the presence of cuprous iodide and bis(triphenylphosphine)palladium dichloride as catalysts and triethylamine as a base to obtain a key intermediate compound 4; the intermediate compound 4 is subjected to a removal of trimethylsilyl under the action of potassium carbonate to obtain an intermediate 5; the intermediate compound 5 and different azide fragments undergo an azide-alkynyl Husigen-Click cycloaddition reaction in the presence of sodium ascorbate and copper sulfate pentahydrate to generate an intermediate compound 6; the intermediate compound 6 is refluxed in a hydrobromic acid and acetic acid system to remove the benzyl protection to generate the target product I or II;
[0025] The synthetic route is as follows:
[0026]
[0027] Reagents and conditions: (i) a) carbonyldiimidazole, O-benzylhydroxylamine, tetrahydrofuran, 80°C, 5-8h; b) sodium hydroxide, ethanol, 85°C, 1-3h; c) acetic acid, rt, 0.5h; (ii) N,N-dimethylformamide, dichloromethane, N-iodosuccinimide, room temperature, 1-3h; (iii) N,N-dimethylformamide, iodoalkanes or iodoaromatic hydrocarbons, carbonic acid Potassium, 20-60°C, 4-8h; (iv) tetrahydrofuran, cuprous iodide, bis(triphenylphosphine)palladium dichloride, triethylamine, trimethylsilyl acetylene, nitrogen, room temperature, 5-8h; (v) methanol, potassium carbonate, room temperature, 1-3h; (vi) sodium ascorbate, copper sulfate pentahydrate, water, tetrahydrofuran, azide, room temperature, 4-5h; (vii) hydrobromic acid, acetic acid, 120°C, 1-2h;
[0028] R1, R2, and n are the same as those shown in the above general formulas I and II.
[0029] The azide is various substituted benzene ring azides, various substituted naphthalene ring azides, various substituted six-membered heterocyclic azides, various substituted five-membered heterocyclic azides, various substituted six-membered and five-membered heterocyclic azides, various substituted six-membered and six-membered heterocyclic azides, various substituted five-membered and five-membered heterocyclic azides, various substituted benzo five-membered heterocyclic azides or various substituted benzo six-membered heterocyclic azides. The substituent is selected from alkyl, cycloalkyl, methoxy, nitro, cyano, amino, trifluoromethyl, ester, halogen, 2,6-diF, 2,5-diF, 3,4-diF, 2,4-diF, 2-F,4-CF3, 3-F,4-CF3, CONH2, SO2NH2, SO2CH3, NHMe, NHCOMe, NHSO2Me or NHSO2CF3.
[0030] 3. Application of N-hydroxythienopyrimidinedione derivatives
[0031] The present invention discloses the results of screening the anti-orthopoxvirus activity of N-hydroxythienopyrimidinedione derivatives and their first application as orthopoxvirus inhibitors. Experiments prove that the N-hydroxythienopyrimidinedione derivatives of the present invention can be used as orthopoxvirus inhibitors for preparing anti-orthopoxvirus drugs.
[0032] Anti-pox virus activity and toxicity experiments of target compounds
[0033] The N-hydroxythienopyrimidinedione derivatives synthesized according to the above method were screened for activity against orthopoxviruses (monkeypox virus, vaccinia virus, cowpox virus and camelpox virus). The activity and toxicity data are listed in Table 1, with cidofovir, brincidofovir and tecoviride as positive controls. As shown in Table 1, among the four newly synthesized N-hydroxythienopyrimidinedione compounds, Z1 and Z2 showed significant antiviral activity against monkeypox virus and camelpox virus, which was better than the positive drug cidofovir. At the same time, the two compounds showed low cytotoxicity (MCC Z1 ≥100 μM, MCC Z2 ≥100μM), which has further research and development value.
[0034] The N-hydroxythienopyrimidinedione derivatives of the present invention are a series of orthopoxvirus inhibitors with novel structures and can be used as anti-orthopoxvirus lead compounds.
[0035] The N-hydroxythienopyrimidinedione derivatives of the present invention can be used as orthopoxvirus inhibitors, and specifically, can be used as orthopoxvirus inhibitors for preparing anti-orthopoxvirus drugs.
[0036] An anti-orthopoxvirus pharmaceutical composition comprises the N-hydroxythienopyrimidinedione derivative of the present invention and one or more pharmaceutically acceptable carriers or excipients. DETAILED DESCRIPTION
[0037] The following examples are provided to help understand the present invention, but they cannot limit the content of the present invention.
[0038] The synthetic route involved in the embodiment is as follows:
[0039]
[0040] Example 1: Preparation of the key intermediate 3-(benzyloxy)-1-(cyclobutylmethyl)-6-ethynylthienopyrimidine-2,4(1H,3H)-dione (5-1, 5-2)
[0041] Weigh 2-aminothiophene-3-carboxylic acid methyl ester (3.14 g, 20.00 mmol), carbonyldiimidazole (8.11 g, 50.00 mmol) and o-benzylhydroxylamine (3.07 g, 25.00 mmol) in 30 mL of tetrahydrofuran, heat to 75 ° C and reflux for 5 h. After the reaction is completed by TLC, evaporate the tetrahydrofuran, add sodium hydroxide (1.60 g, 40.00 mmol) and 30 mL of ethanol, and reflux at 80 ° C for 1 h. After the reaction is completed by TLC, the reaction solution is cooled to room temperature, acidified with glacial acetic acid to produce a large amount of white precipitate, filtered, washed with ethanol and water in turn, and dried to obtain the crude intermediate 3-(benzyloxy)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (1), a light yellow solid, with a yield of 62%. 1 H NMR(400MHz,DMSO-d6)δ12.50(s,1H,NH),7.58–7.55(m,2H,Ph-H),7.43–7.40(m,2H,Ph-H),7.21(d,J=5.6Hz,1H, C4-thienopyrimidinone-H),7.17(d,J=5.6Hz,1H,C3-thienopyrimidinone-H),5.06(s,2H,O-CH2).ESI-MS:m / z 571.25[2M+Na] + ,C 13 H 10 N2O3S(274.04).
[0042] The crude intermediate 1 (4.11 g, 15 mmol) obtained above was dissolved in 20 mL of N,N-dimethylformamide, and N-iodosuccinimide (3.71 g, 16.5 mmol) was added in batches and stirred at room temperature for 1 h. After the reaction was completed by TLC detection, 80 mL of saturated sodium chloride was added to the reaction solution to produce a large amount of white precipitate, which was filtered out and dried for use to obtain the crude intermediate 3-(benzyloxy)-6-iodothieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione (2-1), a white solid, with a yield of 75%. ESI-MS: m / z 423.25[M+Na] + ,C 13 H9IN2O3S(399.94).
[0043] Weigh 3-amino-5-iodothiophene-2-carboxylic acid methyl ester (5.66g, 20.00mmol), carbonyldiimidazole (8.11g, 50.00mmol) and o-benzylhydroxylamine (3.07g, 20.00mmol) in 30mL tetrahydrofuran, heat to 75℃ and reflux for 5h. After the reaction is completed by TLC, evaporate the solvent, add 30mL ethanol to the residue to dissolve, add sodium hydroxide (1.60g, 40.00mmol) and continue to reflux for 1h. After the reaction is completed by TLC, cool to room temperature, add glacial acetic acid to acidify to produce a large amount of white precipitate, filter, wash the precipitate with ethanol and water in turn, and dry to obtain crude 3-(benzyloxy)-6-iodothieno[3,2-d]pyrimidine-2,4-(1H,3H)-dione (2-2), light yellow solid, yield: 59%. ESI-MS: m / z 822.49[2M+Na] + ,C 13 H9IN2O3S(399.94).
[0044] The above intermediate 2-1 (or 2-2) (6.00 g, 15.00 mmol) was added to 20 mL of N, N-dimethylformamide, and then potassium carbonate (4.15 g, 30.00 mmol) and bromomethylcyclobutane (3.35 g, 22.50 mmol) were added to the solution, and stirring was continued at room temperature for 4 h. After the reaction was completed by TLC detection, 100 mL of ice water was added to the mixed solution to produce a large amount of white precipitate, which was filtered and washed with water to obtain 3-(benzyloxy)-1-(cyclobutylmethyl)-6-ethynyl 3-(benzyloxy)thienopyrimidine-2,4(1H,3H)-dione (3-1, 3-2).
[0045] 3-(Benzyloxy)-1-(cyclobutylmethyl)-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (3-1): white solid, yield: 59%, 1H NMR(400MHz,DMSO-d6)δ7.56(s,1H,C3-thienopyrimidinone-H),7.55–7.52(m,2H,Ph-H),7.41(dd,J=5.0,2.1Hz,3H,Ph-H),5.05(s,2H, O-CH2),3.93(d,J=7.2Hz,2H,CH2),2.76(p,J=7.4Hz,1H,CH),2.00–1.95(m,2H,CH2),1.84–1.79(m,4H,2×CH2).ESI-MS:m / z468.97[M+H] + ,C 18 H 17 IN2O3S(468.00).
[0046] 3-(Benzyloxy)-1-(cyclobutylmethyl)-6-ethynyl 3-(benzyloxy)thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione (3-2): white solid, yield: 63%, 1 H NMR(400MHz,DMSO-d6)δ7.78(s,1H,C3-thienopyrimidinone-H),7.55–7.52(m,2H,Ph-H) ,7.41–7.39(m,3H,Ph-H),5.06(s,2H,O-CH2),4.05(d,J=7.3Hz,2H,CH2),2.67(p,J=7.3Hz 1H,CH),1.96–1.89(m,2H,CH2),1.82–1.75(m,4H,2×CH2).ESI-MS:m / z 500.62[M+Na] + ,C 18 H 17 IN2O3S(468.00).
[0047] To a 40 mL anhydrous tetrahydrofuran solution containing 3-(benzyloxy)-1-(cyclobutylmethyl)-thienopyrimidine-2,4(1H,3H)-dione (3-1, 3-2) (4.68 g, 10 mmol), bis(triphenylphosphine)palladium dichloride (0.35 g, 0.5 mmol), cuprous iodide (0.38 g, 2 mmol) and triethylamine (5.56 mL, 40 mmol) were added in sequence, and trimethylsilyl acetylene (3.11 mL, 22 mmol) was added by injection under nitrogen protection, and stirred at room temperature for 8 h. After the reaction was completed by TLC detection, the reaction solution was filtered through diatomaceous earth, concentrated and separated by Flash column to obtain the intermediate 3-benzyloxy-1-(cyclobutylmethyl)-6-((trimethylsilyl)ethynyl)-thienopyrimidine-2,4(1H,3H)-dione (4-1, 4-2). The obtained intermediate (4-1, 4-2) (2.19 g, 5 mmol) was dissolved in 20 mL of methanol solution, potassium carbonate (1.38 g, 10 mmol) was added, and the mixture was stirred at room temperature for 1 h. After the reaction was completed by TLC, methanol was evaporated, 50 mL of aqueous solution was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated, and finally recrystallized in methanol to obtain the key intermediate 3-benzyloxy-1-(cyclobutylmethyl)-6-ethynyl-thienopyrimidine-2,4(1H,3H)-dione (5-1, 5-2).
[0048] 3-Benzyloxy-1-(cyclobutylmethyl)-6-ethynyl-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (5-1), white solid, yield: 65%, melting point: 150-152°C. 1 H NMR(400MHz,DMSO-d6)δ7.57(s,1H,C3-thienopyrimidinone-H),7.56–7.53(m,2H,Ph-H),7.45–7.39(m,3H,Ph-H),5.06(s,2H,O-CH2 ),4.77(s,1H,C≡CH),3.96(d,J=7.1Hz,2H,CH2),2.82–2.73(m,1H,CH),2.03–1.95(m,2H,CH2),1.87–1.79(m,4H,2×CH2).ESI-MS:m / z 405.21[M+K] + ,C 20 H 18 N2O3S(366.10).
[0049] 3-Benzyloxy-1-(cyclobutylmethyl)-6-ethynyl-thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione (5-2), pale yellow solid, yield: 56%, melting point: 156-158°C.1 H NMR(400MHz,DMSO-d6)δ7.77(s,1H,C3-thienopyrimidinone-H),7.56–7.53(m,2H,Ph-H),7.45–7.38(m,3H,Ph-H),5.12(s,1H,C≡CH) ,5.08(s,2H,O-CH2),4.07(d,J=7.2Hz,2H,CH2),2.72–2.65(m,1H,CH),1.96–1.90(m,2H,CH2),1.82–1.76(m,4H,2×CH2).ESI-MS:m / z 405.45[M+K] + ,C 20 H 18 N2O3S (366.10). Example 2: Preparation of target products Z1-Z4
[0050] The key intermediate 3-benzyloxy-1-(cyclobutylmethyl)-6-ethynyl-thienopyrimidine-2,4(1H,3H)-dione (5-1, 5-2) (0.70mmol) and azide prepared from substituted benzyl halide (1.05mmol) were added to a mixed solvent of tetrahydrofuran and water (v / v=4:1, 15mL). Then, a 1M freshly prepared aqueous solution of sodium ascorbate (0.195mmol) and a 7.5% aqueous solution of copper sulfate pentahydrate (0.065mmol) were added to the solution and stirred at room temperature for 5h. After the reaction was completed by TLC detection, 20mL of water was added to the reaction solution and a large amount of precipitate was generated. The filter cake was filtered and washed with water, and then recrystallized in methanol to obtain intermediates Z1a-Z4a of the target product. Add 2 mL of 48% hydrobromic acid and 2 mL of glacial acetic acid to the target intermediate Z1a-Z4a (0.6 mmol), and heat under reflux at 120°C for 2 h. After the reaction is completed by TLC, the reaction solution is cooled to room temperature, concentrated under reduced pressure to obtain the crude target product, and then recrystallized in methanol to obtain the target product Z1-Z4.
[0051]
[0052] The operation is the same as above, and the azide used is 1-(azidomethyl)-3-fluoro-4-(trifluoromethyl)benzene. Z1 is a white solid, yield: 60%, melting point: 232-234°C. 1 H NMR (400MHz, DMSO-d6) δ10.77(s,1H,OH),8.73(s,1H,C3-thienopyrimidinone-H),7.85(t,J=7.9Hz,2H,Ph-H),7.66(s,1H,C 15-triazole-H),7.55(d,J=11.5Hz,1H,Ph-H),7.34(d,J=8.1Hz,1H,Ph-H),5.82(s,2H,CH2),4.03( d,J=7.3Hz,2H,CH2),2.84(p,J=7.5Hz,1H,CH),2.04–1.98(m,2H,CH2),1.87–1.81(m,4H,2×CH2). 13 C NMR (100MHz, DMSO-d6) δ159.33 (d, J = 253.1Hz), 155.82, 151.05, 149.58, 143.86 (d, J = 7.4Hz), 141.40, 128.48 (d, J = 4.9Hz), 125.02 (d, J=4.9Hz),124.35(d,J=4.3Hz),122.27,119.87,117.34,117.12,115.30,54.15,52.51,33.70,26.19,18.39.ESI-MS:m / z496.22[M+H] + ,C 21 H 17 F4N5O3S(495.10).
[0053]
[0054] The operation is the same as above, and the azide used is 1-(azidomethyl)-2-fluoro-4-(trifluoromethyl)benzene. Z2 is a white solid, yield: 56%, melting point: 197-199°C. 1 H NMR(400MHz,DMSO-d6)δ10.73(s,1H,-OH),8.72(s,1H,C3-thienopyrimidinone-H),7.84–7.78(m,1H,Ph-H),7.69-7.66(m,2H,C 15 -triazole-H,Ph-H),7.62(t,J=7.6Hz,1H,Ph-H),5.84(s,2H,CH2),4.02(d,J=7.3Hz, 2H,CH2),2.84(p,J=7.6Hz,1H,CH),2.03-1.97(m,2H,CH2),1.89–1.81(m,4H,2×CH2). 13C NMR(100MHz,DMSO-d6)δ160.42(d,J=249.8Hz),155.79,151.06,149.56,141.30,132.50(d,J=3.7Hz),127.66(d,J=14.9Hz),124.35,1 22.34(d,J=3.8Hz),122.17,119.92,115.31,113.93(d,J=4.0Hz),113.66(d,J=3.9Hz),54.13,47.53,33.70,26.19,18.38.ESI-MS:m / z 496.23[M+H] + ,C 21 H 17 F4N5O3S(495.10).
[0055]
[0056] The operation was the same as above, and the azide used was 1-(azidomethyl)-3-fluoro-4-(trifluoromethyl)benzene. Z3 was a white solid with a yield of 64% and a melting point of 186-188°C. 1 H NMR (400MHz, DMSO-d6) δ10.77(s,1H,-OH),8.83(s,1H,C3-thienopyrimidinone-H),7.86(t,J=7.9Hz,1H,Ph-H),7.77(s,1H,C 15 -triazole-H,),7.57(d,J=11.5Hz,1H,Ph-H),7.36(d,J=8.1Hz,1H,Ph-H),5.87(s,2H,CH2),4.09(d,J=7.3Hz,2H CH2),2.75(p,J=7.3Hz,1H,CH),1.98–1.92(m,2H,CH2),1.87–1.80(m,4H,2×CH2). 13 C NMR (100MHz, DMSO-d6) δ159.35(d,J=252.4Hz),155.48,150.58,145.17,143.79(d,J=7.8Hz),141.36,140.99,128.54(d, J=4.8Hz),125.04(d,J=3.4Hz),123.83,117.37,117.16,114.62,109.86,52.60,50.83,34.29,25.82,18.31.ESI-MS:m / z 496.08[M+H] + ,C 21 H 17F4N5O3S(495.10).
[0057]
[0058] The operation was the same as above, and the azide used was 1-(azidomethyl)-2-fluoro-4-(trifluoromethyl)benzene. Z4 was a white solid, with a yield of 58% and a melting point of 240-242°C. 1 H NMR (400MHz, DMSO-d6) δ10.75(s,1H,-OH),8.82(s,1H,C3-thienopyrimidinone-H),7.82(d,J=10.0Hz,1H,Ph-H),7.79(s,1H,C 15 -triazole-H,),7.72–7.62(m,2H,Ph-H),5.90(s,2H,CH2),4.09(d,J=7.4Hz,2H, CH2),2.75(p,J=7.3Hz,1H,CH),1.99–1.94(m,2H,CH2),1.87–1.81(m,4H,2×CH2). 13 C NMR (100MHz, DMSO-d6) δ160.45(d,J=249.9Hz),155.47,150.57,145.19,141.27,140.99,132.54(d,J=3.7Hz),127.60(d,J=15.1 Hz),123.69,122.42,114.63,113.96(d,J=3.8Hz),113.72(d,J=4.0Hz),109.84,50.82,47.67,34.28,25.81,18.31.ESI-MS:m / z 496.14[M+H] + ,C 21 H 17 F4N5O3S(495.10).
[0059] Example 3: In vitro anti-orthopoxvirus activity test of target compounds (HEL cells)
[0060] Test Principle
[0061] After the virus infects the cells, due to the limitation of the solid medium, the released virus can only spread from the initially infected cells to the periphery. After several proliferation cycles, a localized diseased cell area is formed, which is the virus plaque. Theoretically, a plaque is formed by a virus particle of the initially infected cell, so this technology is often used for virus particle counting and virus clone separation.
[0062] Test method:
[0063] Plaque assay (Plaque assay, PFU)
[0064] After digestion and centrifugation of HEL cells, the cells were counted and plated in 96-well plates. After culturing for 24 hours at 37°C and 5% CO2, 100 CCID50 of virus was added to infect the cells. After 1 hour, the residual virus was removed, and different concentrations of compounds were added. The cells were incubated for another 1 hour, and then covered with 1.6% carboxymethyl cellulose diluted in DMEM. After 3 days of culture, the monolayer cells were fixed and stained with 3.7% formaldehyde, 0.1% crystal violet and 1.5% methanol. The plaques were counted microscopically, and the concentration of the compound that reduced the number of plaques by 50% was calculated as the antiviral activity of the target compound (EC 50 ).
[0065] Cytotoxicity testing is based on the inhibitory effect of the test compound on cell growth. First, a quantitative amount of 5×10 3 The HEL cells proliferating at a rate of 100 μg / mL were then added with serially diluted test compounds and incubated for 3 days. The HEL cells in each well were then counted using a Coulter counter. The minimum concentration of the compound required to cause changes in normal cell morphology visible under a microscope was the MCC.
[0066] Table 1 Anti-orthopoxvirus activity and toxicity of N-hydroxythienopyrimidinedione derivatives (HEL cells)
[0067]
[0068] a EC 50 : The concentration of compound that inhibits the formation of 50% of viral plaques. <A<10μM,10μM<B<100μM,C> 100μM.
[0069] b MCC: The minimum concentration of a compound required to cause microscopic changes in normal cell morphology.
[0070] Experimental conclusion analysis: Among the four newly synthesized N-hydroxythienopyrimidine dione compounds, Z1 and Z2 showed significant antiviral activity against monkeypox virus and camelpox virus, which was better than the positive drug cidofovir. At the same time, the two compounds showed low cytotoxicity (MCC Z1 ≥100 μM, MCC Z2 ≥100μM), which has further research and development value.
Claims
1. An N-hydroxythienopyrimidinedione derivative, or a pharmaceutically acceptable salt thereof, having a structure shown in general formula I or II: n = 0, 1, 2 or 3; R1 is: hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R2 is: C1-C6 alkyl, OC1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, OC3-C6 cycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered heterocycle, substituted or unsubstituted five-membered heterocycle, substituted or unsubstituted six-membered and five-membered heterocycle, substituted or unsubstituted six-membered and six-membered heterocycle, substituted or unsubstituted five-membered and five-membered heterocycle, substituted or unsubstituted benzo five-membered heterocycle, substituted or unsubstituted benzo six-membered heterocycle; The substituents in R1 and R2 are selected from alkyl, cycloalkyl, methoxy, nitro, cyano, amino, trifluoromethyl, ester, halogen, 2,6-diF, 2,5-diF, 3,4-diF, 2,4-diF, 2-F,4-CF3, 3-F,4-CF3, CONH2, SO2NH2, SO2CH3, NHMe, NHCOMe, NHSO2Me or NHSO2CF3.
2. The N-hydroxythienopyrimidinedione derivative according to claim 1, characterized in that: R1 is methyl, ethyl, isopropyl, methylenecyclopropyl or methylenecyclobutyl; n=1, R2 is a substituted benzene ring having the general formula a; wherein R3 is F, Cl, Br, Me, OMe, CN, NO2, NH2, 2,6-diF, 2,5-diF, 3,4-diF, 2,4-diF, 2-F,4-CF3, 3-F,4-CF3, CONH2, SO2NH2, SO2CH3, NHMe, NHCOMe, NHSO2Me or NHSO2CF3.
3. The N-hydroxythienopyrimidinedione derivative according to claim 1, characterized in that: The pharmaceutically acceptable salt of the compound is sodium salt, hydrochloride, sulfate, tartrate or citrate.
4. The N-hydroxythienopyrimidinedione derivative according to claim 2, characterized in that is one of the following compounds:
5. The method for preparing N-hydroxythienopyrimidinedione derivatives according to claim 1, characterized in that Here are the steps: 2-aminothiophene-3-carboxylic acid methyl ester is used as a starting material, and reacts with carbonyldiimidazole and o-benzylhydroxylamine to form an intermediate compound 1; the intermediate compound 1 reacts with N-iodosuccinimide to form an intermediate compound 2 (or 3-amino-5-iodothiophene-2-carboxylic acid methyl ester directly reacts with carbonyldiimidazole and o-benzylhydroxylamine to form an intermediate compound 2); the intermediate compound 2 undergoes a nucleophilic substitution reaction under the action of potassium carbonate to form an intermediate compound 3; the intermediate compound 3 is reacted with cuprous iodide and diisocyanate to form an intermediate compound 3; (Triphenylphosphine) palladium dichloride is used as a catalyst and triethylamine is used as a base to undergo a Sonogaoka coupling reaction to obtain a key intermediate compound 4; the intermediate compound 4 is subjected to the removal of the trimethylsilyl group under the action of potassium carbonate to obtain an intermediate 5; the intermediate compound 5 and different azide fragments undergo an azide-alkynyl Husigen-Click cycloaddition reaction in the presence of sodium ascorbate and copper sulfate pentahydrate to generate an intermediate compound 6; the intermediate compound 6 is refluxed in a hydrobromic acid and acetic acid system to remove the benzyl protection to generate the target product I or II; The synthetic route is as follows: Reagents and conditions: (i) a) carbonyldiimidazole, O-benzylhydroxylamine, tetrahydrofuran, 80°C, 5-8h; b) sodium hydroxide, ethanol, 85°C, 1-3h; c) acetic acid, rt, 0.5h; (ii) N,N-dimethylformamide, dichloromethane, N-iodosuccinimide, room temperature, 1-3h; (iii) N,N-dimethylformamide, iodoalkanes or iodoaromatic hydrocarbons, carbonic acid Potassium, 20-60°C, 4-8h; (iv) tetrahydrofuran, cuprous iodide, bis(triphenylphosphine)palladium dichloride, triethylamine, trimethylsilyl acetylene, nitrogen, room temperature, 5-8h; (v) methanol, potassium carbonate, room temperature, 1-3h; (vi) sodium ascorbate, copper sulfate pentahydrate, water, tetrahydrofuran, azide, room temperature, 4-5h; (vii) hydrobromic acid, acetic acid, 120°C, 1-2h; R1, R2, and n are the same as those shown in the general formula I or II of claim 1; The azide is various substituted benzene ring azides, various substituted naphthalene ring azides, various substituted six-membered heterocyclic azides, various substituted five-membered heterocyclic azides, various substituted six-membered and five-membered heterocyclic azides, various substituted six-membered and six-membered heterocyclic azides, various substituted five-membered and five-membered heterocyclic azides, various substituted benzo five-membered heterocyclic azides or various substituted benzo six-membered heterocyclic azides; the substituent is selected from alkyl, cycloalkyl, methoxy, nitro, cyano, amino, trifluoromethyl, ester, halogen, 2,6-diF, 2,5-diF, 3,4-diF, 2,4-diF, 2-F,4-CF3, 3-F,4-CF3, CONH2, SO2NH2, SO2CH3, NHMe, NHCOMe, NHSO2Me or NHSO2CF3.
6. Use of the compound according to any one of claims 1 to 4 in the preparation of anti-orthopoxvirus drugs.
7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 4 and one or more pharmaceutically acceptable carriers or excipients.
Citation Information
Patent Citations
N-hydroxyl heterocycle pyrimindine diketone derivative and preparation method and application thereof
CN105669653A
Heterocyclic aza-diketone derivative as well as preparation method and application thereof
CN119080751A
Thienopyrimidinediones and their use in the modulation of autoimmune disease
CN1761672A
